Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study

Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study

Abstract Background Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has shown evidence of cardiovascular benefit in patients with type 2 diabetes mellitus (T2DM). Currently metformin is the guideline-recommended first-line treatment. We aimed to investigate the benefit of SGLT2i vs metformin as...

Full description

Bibliographic Details
Main Authors: Tien-Hsing Chen, Yan-Rong Li, Shao-Wei Chen, Yu-Sheng Lin, Chi-Chin Sun, Dong-Yi Chen, Chun-Tai Mao, Michael Wu, Chih-Hsiang Chang, Pao-Hsien Chu, Victor Chien-Chia Wu
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes mellitus
Sodium-glucose co-transporter 2 inhibitor
Metformin
Cardiovascular outcome
Online Access:http://link.springer.com/article/10.1186/s12933-020-01169-3

Internet

http://link.springer.com/article/10.1186/s12933-020-01169-3

Similar Items